Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.69 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.59 |
| ▸ | PAK4 | O96013 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347544 | 1.00 | BCL2L1 (0.69) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL2196804 | 0.98 | BCL2L1 (0.67) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| SCHEMBL28162040 | 0.85 | DYRK1A (0.51) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| SCHEMBL8958420 | 0.85 | BCL2L1 (0.65) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| SCHEMBL31356465 | 0.83 | BCL2L1 (0.74) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| SCHEMBL7209477 | 0.83 | BCL2L1 (0.74) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| SCHEMBL6321234 | 0.83 | BCL2L1 (0.74) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| SCHEMBL28162038 | 0.83 | DYRK1A (0.50) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| Tetrazole SCHEMBL6927480 | 0.82 | SLC9A1 (0.49) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| SCHEMBL4070224 | 0.82 | BCL2L1 (0.61) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707941-A | Quinolinone compound, preparation method and application thereof | 苏州旺山旺水生物医药股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-114450275-B | Heteroaryl aminopyridine alcohol derivatives and pharmaceutical composition for preventing or treating autoimmune diseases comprising the same as active ingredient | 因诺沃治疗有限公司 | 2024-11-19 | — | — | CN | claimed |
| EP-4416268-A1 | METHODS FOR PRODUCING CARTILAGE AND BONES | Murdoch Children's Research Institute (AU) | 2024-08-21 | — | — | EP | claimed |
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-05-04 | — | — | US | claimed |
| WO-2023060322-A1 | METHODS FOR PRODUCING CARTILAGE AND BONES | MURDOCH CHILDREN'S RESEARCH INSTITUTE (AU) | 2023-04-20 | — | — | WO | claimed |
| EP-3911646-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2023-03-01 | — | — | EP | claimed |
| EP-4098258-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-12-07 | — | — | EP | claimed |
| US-12636275-B2 | Pharmaceutical use of ketoamide-based compound | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2026-05-26 | — | — | US | disclosed |
| WO-2026107062-A1 | STAT6 DEGRADERS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4680255-A1 | METHODS FOR PRODUCING STABLE HUMAN CHONDROCTYES AND THEIR USE FOR PROMOTING CARTILLAGE GROWTH AND REPAIR | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4561991-A1 | NOVEL HETEROCYCLES AS SPLA2-X INHIBITORS | Cayman Chemical Company, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4532699-A1 | TRIPLE TISSUE CULTURE FUSION | IMBA-Institut für Molekulare Biotechnologie GmbH (AT) | 2025-04-09 | — | — | EP | disclosed |
| EP-4098258-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-12-07 | — | — | EP | disclosed |
| CN-115443129-A | KCNT1 inhibitors and methods of use | 普拉西斯精密医药公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-110114353-B | Benzo [ b ] thiophene amide derivative and application thereof | 山东大学 | 2022-04-22 | — | — | CN | disclosed |
| CN-110114353-B | Benzo [ b ] thiophene amide derivative and application thereof | 山东大学 | 2022-04-22 | — | — | CN | disclosed |
| US-20220112177-A1 | KETOAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | FUDAN UNIVERSITY (CN) | 2022-04-14 | — | — | US | disclosed |
| US-20220089584-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2022-03-24 | — | — | US | disclosed |
| CN-113979915-A | Dopamine D2Receptor dibit ligand type compound and application | 常州大学 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112177-A1 | KETOAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | ACE, REN, ACE2 | BCL2L1 4751/4885SLC9A1 1027/4885HDAC3 27/4885 |
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | CTSL, CTSV, CTSS | BCL2L1 915/4885SLC9A1 1436/4885HDAC3 145/4885 |
| US-20220089584-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | BCL2L1 2334/4885SLC9A1 91/4885HDAC3 452/4885 |
| US-20250136570-A1 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | HDAC1, HDAC7, HDAC5 | BCL2L1 1273/4885SLC9A1 2315/4885HDAC3 9/4885 |
| US-12636275-B2 | Pharmaceutical use of ketoamide-based compound | CTSV, CTSL, CTSS | BCL2L1 873/4885SLC9A1 857/4885HDAC3 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.